Figure 2.

Inhibition of TP53 can alleviate CRISPR/Cas9-associated cell cycle arrest. (A) Schematic of Cas9 reporter plasmids containing a short-hairpin cassette against TP53 or two short hairpin cassettes against TP53 and RB1. (B) Schematic of experimental design. (C) Bar graph of Cas9+ normalized percentages of EdU+ and EdU- cells for indicated treatments. n = at least two independent experiments each consisting of three technical replicates for each transfection. Data is shown as the mean ± SEM. **P < 0.009. Data were analyzed via an ordinary two-way ANOVA followed by a post-hoc Dunnett's multiple comparisons test, where each treatment was compared to wild-type RPE-1 cells treated with wild-type Cas9.